News

GLHF’s Madison’s Best Bloody will be held at the Edgewater Hotel, 1001 Wisconsin Place, Madison, WI, on Sunday April 28 from 11:30…

Last month, GLHF headed to Madison for our annual Wisconsin Legislative Day – a chance to share with lawmakers the true reality…

When GLHF started Milwaukee’s Best Bloody seven years ago, we were looking for a fresh way to raise critical funds and awareness…

Cell therapy with endothelial progenitor cells and stem cells genetically engineered to produce a functional clotting factor VIII (FVIII) may provide a…

The National Hemophilia Foundation (NHF) has advocated for the needs and interests of people affected by hemophilia and related bleeding disorders for…

It’s time to put on your red ties again and join us for the 2019 Red Tie Campaign! This March, during Bleeding…

uniQure is excited to announce that updated data from their Phase 2B dose-confirmation study of AMT-061, an investigational gene therapy for the…

by: Derek L. Markley It has been more than eight years since St. Jude Children’s Research Hospital, University College London, and the…

by: Laurie Kelley Our world is biased toward visual information and learning, because humans are mainly visual beings. From advertising to teaching…

The National Hemophilia Foundation (NHF) has announced a new two-year pilot program that aims to improve the efficacy of patient infusion logs…

by: Paul Clement It’s an exciting time for people with inhibitors. In addition to bypassing agents, new products may prevent or control…

Physical therapists (PTs) at hemophilia treatment centers (HTCs) often consult with hemophilia patients about engaging in new physical activities like exercise, team/individual…

Catalyst Biosciences, Inc recently reported updated interim data from their phase 2/3, multinational clinical study of marzeptacog alfa (MarzAA), a subcutaneous (administered…

Part of GLHF’s mission is to educate the bleeding disorders community about opportunities and information that can benefit them and impact their…

This past January, GLHF hosted more than 40 children, families, Hemophilia Treatment Center staff and donors to celebrate Camp Klotty Pine’s five…

Discover the resources and information you need to take advantage of the educational, career and scholarship opportunities that are available to the…

Takeda Pharmaceutical Company Limited recently announced the completion of its acquisition of Shire plc on January 8, 2019. The acquisition was approved…

The most prevalent bleeding disorder, von Willebrand disease (VWD), affects more than 3 million Americans, about 1% of the population. And, its…

by: Steve Place I have lived for 64 years with mild hemophilia and have voluminous experience, from which I came to my…

Sangamo Therapeutics, Inc. recently announced it has treated the first patient in a Phase 1/2 clinical trial evaluating SB-FIX, the company’s investigational…

On December 14, 2018, a Texas judge ruled in Texas vs. United States, a case challenging the constitutionality of the Affordable Care…

by: Derek Markley As a father, I will be the first to say that learning about hemophilia leads to a number of…

In the age of high deductibles and patient out of pocket expenditures, more and more people depend on copay assistance to afford…

The National Hemophilia Foundation’s (NHF) Medical and Scientific Advisory Council has issued two new documents on November 21, 2018 that were approved…